Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Duality Biotherapeutics, Inc. (9606.HK)
HKD235.40
+12.60 (+5.66%)
CN HKSE Healthcare Biotechnology
Address
Units 1103-1106, Building A, 868 Yinghua Road 201204
Shanghai, CN
Shanghai, CN
CEO
Zhongyuan Zhu
Website
dualitybiologics.com
IPO
2025-04-15
ISIN KYG2929M1087
Description
Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded by Zhu Zhong Yuan on July 3, 2019, and its main offices are situated in Shanghai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD235.40
+12.60 (+5.66%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
2.10
Float Shares
61.35M
Free Float %
67.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.84% | +2.55% | -18.26% | -28.38% | -34.68% | -24.35% | +6.92% | +10.05% | +10.05% | +10.05% | +10.05% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
235.40
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
6.49
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-7.1% Q2'25: +22.9% (vs Q1'24)
-
EPS growth Biotechnology: +29.7%-207.1% Q2'25: -35.6% (vs Q1'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-6.0% Q2'25: +48.0% (vs Q1'24)
-
EBIT margin Biotechnology: +0.0%-23.1% Q2'25: +9.5% (vs Q1'24)
-
ROIC Biotechnology: -16.1%— Q2'25: -29.3% (vs Q1'24)
-
Share dilution Biotechnology: -3.4%-21.7% ★ Q2'25: +421.3% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.37× Q2'25: 0.61× (vs Q1'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 5 EPS Ana. |
Dec 2027 8 Rev. Ana. 5 EPS Ana. |
Dec 2028 6 Rev. Ana. 2 EPS Ana. |
Dec 2029 7 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
1.80B
est: 1.40B (+29.2%)
|
1.71B
1.09B – 2.10B
+22.7% YoY
|
1.65B
511.19M – 2.32B
-3.6% YoY
|
2.25B
1.08B – 2.95B
+36.4% YoY
|
4.55B
2.18B – 5.97B
+102.2% YoY
|
| EBITDA |
-404.27M
est: -646.50M (+37.5%)
|
-793.05M
-971.69M – -506.06M
-22.7% YoY
|
-764.51M
-1.07B – -236.79M
+3.6% YoY
|
-1.04B
-1.37B – -499.57M
-36.4% YoY
|
-2.11B
-2.77B – -1.01B
-102.2% YoY
|
| EBIT |
-416.27M
est: -651.21M (+36.1%)
|
-798.83M
-978.77M – -509.75M
-22.7% YoY
|
-770.08M
-1.08B – -238.52M
+3.6% YoY
|
-1.05B
-1.38B – -503.21M
-36.4% YoY
|
-2.12B
-2.79B – -1.02B
-102.2% YoY
|
| Net Income |
-2.53B
est: -1.80B (-40.1%)
|
-300.60M
-745.21M – -63.67M
+83.3% YoY
|
-418.85M
-859.33M – -267.95M
-39.3% YoY
|
-393.12M
-552.39M – -126.94M
+6.1% YoY
|
-87.85M
-123.44M – -28.37M
+77.7% YoY
|
| SGA |
168.57M
est: 3.34B (-94.9%)
|
4.09B
2.61B – 5.02B
+22.7% YoY
|
3.95B
1.22B – 5.54B
-3.6% YoY
|
5.38B
2.58B – 7.06B
+36.4% YoY
|
10.89B
5.22B – 14.28B
+102.2% YoY
|
| EPS |
-38.79
est: -27.69 (-40.1%)
|
-4.61
-11.44 – -0.98
+83.3% YoY
|
-6.43
-13.19 – -4.11
-39.3% YoY
|
-6.03
-8.48 – -1.95
+6.1% YoY
|
-1.35
-1.89 – -0.44
+77.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
597.82M
OE per share TTM
14.34
Owner's Yield
4.07%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 61 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.51% | 331.8K | 0.59% |
| 2 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.21% | 2.41M | 0.40% |
| 3 | iShares Ageing Population UCITS ETF AGED.L | 0.16% | 1.43M | 0.40% |
| 4 | UBS Solactive China Technology UCITS ETF USD acc CQQQ.SW | 0.15% | 576.4K | 0.47% |
| 5 | UBS Solactive China Technology UCITS ETF hEUR acc CITE.MI | 0.15% | 573.2K | 0.50% |
| 6 | Schwab International Small-Cap Equity ETF SCHC | 0.07% | 3.83M | 0.06% |
| 7 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.07% | 51.3K | 0.74% |
| 8 | iShares International Small-Cap Equity Factor ETF ISCF | 0.06% | 396.9K | 0.24% |
| 9 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.05% | 170.9K | 0.74% |
| 10 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.05% | 181.0K | 0.72% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-2.45M
Shares Outstanding
90.52M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhongyuan Zhu | Chief Executive Officer & Chairman | 5M | male |
| Shaoren Zhang | CFO, VP of Finance & Executive Director | 3M | male |
| Wen Si | Executive Director of Human Resources | 2M | female |
| Lan Zhou | Vice President of Commercial Strategy | — | female |
| Rong Shi | Vice President of Development Science | — | — |
| Ruiyin Chu | Vice President of Translational Medicine | — | — |
| Haiqing Hua | Senior VP, Head of Drug Discovery & Executive Director | — | — |
| Wing Man Tsang | Joint Company Secretary | — | female |
| Xin Wang | Chief Business Officer | — | male |
| Xin Yu | Vice President & Head of Regulatory Affairs | — | male |
| Yang Qiu | Chief Scientific Officer | — | — |
| Wei Gu | Chief Medical Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9606.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
